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From the Editor’s Desk
The year is flying by and it is time for the latest issue
of LABRAD. This edition of LABRAD is nonthematic and includes diverse range of up-to-date
topics in the expanding field of laboratory medicine.
The LABRAD kicks off with an overview on IgG4
related diseases and its diagnostic challenges. IgG4related disease is a recently recognized syndrome of
unknown etiology most often occurring in middleaged and older men. The Section of Chemical
Pathology has recently started measuring subclass
IgG4 in serum which can assist in the diagnosis of
IgG4-related disease; however confirmed diagnosis
requires a tissue biopsy of the affected organ.
Pathological changes in renal transplant biopsies
either due to immunosuppressive drugs or the
sequelae of the immunosuppressive state has been
discussed later on in the newsletter. One of our
hematology residents has elaborated on complementmediated hemolysis ‘Paroxysmal Nocturnal
Hemoglobinuria’ and how it can be diagnosed by
flow cytometry.
This issue also includes an article on the utility
of Beta-D-Glucan and Galactomannan testing in
diagnosis of invasive fungal infections. Beta-D
Glucan and Galactomannan are fungal cell wall
antigens which can be measured in serum or
bronchoalveolar lavage fluid. These tests have been
recently introduced in the Section of Microbiology.
Elevated Beta-D-Glucan and Galactomannan levels
can help diagnose invasive fungal infections early
and can also guide in commencement of therapy as it

has both diagnostic as well as prognostic impact.
The pace of change in Laboratory Medicine is
dizzying; both in numbers of laboratory tests and
in the complexity of the results, as is the emerging
need to integrate massive data sets to reach a clinical
interpretation. The genomic success stories strongly
suggest that personalized medicine will increase the
role of clinical laboratories in patient management.
These changes have profound implications for the
discipline of Pathology and Laboratory Medicine and
for how laboratory diagnosticians relate to medicine
as a whole. LABRAD gives us an opportunity
to connect to the clinicians, our peers and other
health care providers. All faculty, technologists and
residents are encouraged to keep sending articles or
other contributions (interesting images in cytology,
test/ procedure updates, and quiz) to us. The
Department of Pathology and Laboratory Medicine
members contribute extensively to healthcare,
education and research arenas. Maintaining our
visibility as key players in healthcare is crucial to the
profession, I urge you to please send a small write
up and photographs of your activities to us so that we
could share it with all our readers.
We really hope this issue will provide some cool
reading on a hot day!
Happy reading
Dr Lena Jafri
Associate Editor, LABRAD

An Overview of Immunoglobulin G4-Related
Disease (IgG4-RD)
Dr Sheharbano Imran
Chemical Pathology

Immunoglobulin G4-related disease (IgG4-RD)
is a rare systemic fibro-inflammatory disorder
comprised of a collection of disorders that
share specific pathologic, serologic, and clinical
features. The pathogenesis of IgG4-RD is poorly
understood; findings consistent with both an

autoimmune disorder and an allergic disorder are
present. The common features of IgG4-related
disease are lymphoplasmacytic tissue infiltration
usually accompanied by fibrosis, obliterative
phlebitis, and elevated serum IgG4. However,
approximately 30% of patients have normal serum
3
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IgG4 concentrations despite classic histopathological
and immunohistochemical findings. The hallmark
histopathological features of IgG4-RD are
l

l

l

A dense lymphoplasmacytic (lymphocyte and 			
plasma cells) infiltrate rich in IgG4-positive 			
plasma cells.
Fibrosis, arranged at least focally, in a storiform 		
pattern. ‘Storiform’ is commonly referred to as
meaning ‘having a cartwheel pattern’, but its
literal meaning is the appearance of ‘a woven mat’
The venous channels are obliterated by a dense
lymphoplasmacytic infiltrate, within both the
venous walls and the lumen.

Other histopathological features associated with
IgG4-RD are phlebitis without obliteration of the
lumen and/or tissue with increased numbers of
eosinophil.
IgG4-RD can involve one or multiple sites in
the body (salivary gland, orbits, pancreas, Para
nasal sinus, lacrimal gland, thyroid, pleura, lymph
nodes etc.). With multiorgan involvement, the

sites involved can be affected at the same time
(synchronously) or at different unrelated periods
(metachronously). However, Type 1 autoimmune
pancreatitis is the most frequent manifestation of this
disease. Following medical conditions that have long
been viewed as conditions confined to single organs
are part of the spectrum of IgG4-related disease:
autoimmune pancreatitis, Mikulicz disease, Kuttner’s
tumor, Riedel thyroiditis, eosinophilic angiocentric
fibrosis, multifocal fibrosclerosis, inflammatory
psuedotumor, fibrosing mediastinitis, sclerosing
mesenteritis, retroperitoneal fibrosis, periaortitis/
periarteritis, inflammatory aortic aneurysm,
cutaneous pseudolymphoma, idiopathic hypertrophic
pachymeningitis, idiopathic tubulointerstitial nephritis,
, idiopathic hypocomplementemic tubulointerstitial
nephritis with extensive tubulointerstitial deposits and
idiopathic cervical fibrosis.
Early detection is important to avoid organ damage
and potentially serious complications. Diagnosing
IgG4- RD is challenging and the awareness of this
disease is low. The Clinical Laboratory of Aga Khan
University Hospital has initiated the testing serum
IgG4 which can assist in the diagnoses of IgG-4
related diseases.

Plasma Neutrophil Gelatinase Associated
Lipocalin (NGAL) a Marker of Acute Kidney
Injury
Dr Shabnum Khawaja
Chemical Pathology

Acute kidney injury (AKI) is characterized
functionally by a rapid decline in the glomerular
filtration rate (GFR), and biochemically by the
resultant accumulation of nitrogenous wastes
such as blood-urea nitrogen and creatinine. It has
high incidence in hospitalized patients and poor
prognosis in critically ill patients with a high
mortality rate. At present, serum creatinine is used
to measure the GFR and it is the most commonly
used marker of renal function. Diagnosis of
AKI still entirely based on an increase in serum
creatinine or decrease in urine volume. Due to delay
between changes in serum creatinine and changes
in GFR inhibits the ability to accurately estimate
4

timing of injury and severity of dysfunction
following injury. Unfortunately, serum creatinine is
a delayed and unreliable indicator of AKI, for the
following reasons:
l

l

Serum creatinine level is influenced by multiple
non-renal factors, such as age, gender, muscle
mass, muscle metabolism, diet, medications,
and hydration status.
In AKI, the serum creatinine level can take
several hours or days to reach a new steady 		
state and thus does not reflect the actual
decrease in GFR in the acute setting.

JULY 2015
l

l

l

Because of renal reserve, the serum creatinine
level may not rise until more than 50% of the
kidney function has been lost.
An increase in the serum creatinine level
represents a delayed indication of a functional
change in GFR that lags behind structural
changes that occur in the kidney during the
early stage of AKI.
Serum creatinine measurement does not
allow differentiation between hermodynamically
mediated changes in renal function, such as 		
pre-renal azotemia from intrinsic renal failure or
obstructive uropathy.

NGAL for the prediction of AKI
Neutrophil gelatinase-associated lipocalin (NGAL)
is a single disulphide-bridged polypeptide chain of
178 amino-acid residues with a molecular mass of
25kDa. It is a small protein expressed in neutrophils
and certain epithelia, including the renal tubules.
In healthy person it filtered out of plasma by the
glomeruli when it passes through the kidneys then
reabsorbed back into plasma in the tubules. In kidney
inflammation its expression is greatly increased as a
human immune response to inflammation and injury
to epithelia and accumulation of in blood plasma,
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with increased concentrations in plasma and urine,
could indicate AKI.
It is to be one of the earliest and most robustly
induced proteins in the kidney after ischemic or
nephrotoxic AKI. Its levels rise within two hours
of the insult, making it as an early and sensitive
biomarker of AKI. Plasma NGAL is a biomarker
for the early prediction of AKI following defined
clinical injuries such as cardiopulmonary bypass,
contrast administration and kidney transplantation.
Plasma NGAL can also be used for the early
prediction of AKI, even in heterogeneous clinical
situations where the timing of kidney injury is
unknown, such as in the critical care or emergency
settings. NGAL levels can also discriminate
between true AKI and prerenal azotemia in
unselected patients presenting for emergency
care. Reduction in NGAL levels are becoming
increasingly used as an efficacy marker in trials
for the prevention and/or treatment of AKI. Early
plasma NGAL concentrations are predictive of
dialysis requirement, mortality and length of
hospital stay in a variety of clinical AKI situations.
NGAL is emerging as an excellent standalone
troponin-like biomarker for the prediction of
AKI and its clinical outcomes. It not only aids in
diagnosis but levels also correlate with the severity
of the AKI and with patients outcomes.

Celiac Disease: Biomarkers for Diagnosis and
Monitoring
Dr Hafsa Majid
Chemical Pathology

Celiac Disease (CD) or gluten-sensitive enteropathy
is an autoimmune disease caused by ingestion of
gluten-containing cereals, in genetically predisposed
individuals. It is characterized by inflammation
and atrophy of the small intestinal villi, leading to
reduced nutrients absorption. Clinical symptoms of
CD are fatigue, abdominal pain, diarrhea, effects
of malabsorption such as weight loss and growth
retardation in children, vomiting, constipation,
and bone pains. CD patients may also manifest
with symptoms of nutritional deficiencies such
as osteoporosis, anemia, neuropathies, carditis,
pregnancy problems, or lymphoma. The only effective
treatment for CD is adherence to a gluten-free diet.

The prevalence of symptomatic CD is around
one percent. The frequency of CD is substantially
increased in patients who have a first-degree family
member affected with CD. However, most cases
remain undiagnosed, only patients with classical
variant are investigated and represent only the
tip of the celiac iceberg. Recently, it has become
increasingly evident that CD exists not only in
its classical form, but also more frequently in
asymptomatic or silent forms. These patients do
not have symptoms, but they exhibit CD specific
antibodies and villous atrophy. So a disease which
was once believed to be a rare enteropathy of
childhood is now considered to be a much more
5
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common multi-organ disease. The exact prevalence
of CD in Pakistan is not known, but it is felt to be a
common disorder present in all four provinces.
Disease Pathogenesis
The cause of the pathological process leading to CD
is prolamins, which are protein components of gluten
found in many types of cereal. Gliadin is the most
common occurring prolamin. Prolamins are only
partly digested in the small intestine. The resulting
peptides are taken up into the intestinal wall and
deamidated by the enzyme tissue transglutaminase
(TTG). The immune system of affected individuals
is genetically predisposed to develop immune
reactions against both the deamidated peptides and
transglutaminase. These reactions cause chronic
inflammation and atrophy of the small intestinal villi.
Diagnosis of CD
In recent years, advances in laboratory diagnostic
tests for CD have transformed the way the disease
is diagnosed and monitored, reducing the number
of small bowel biopsies performed significantly.
The target antigens are divided into two groups, first
group includes autoantibodies [Anti endomysial
(EMA) and anti-TTG] antibody tests, and second
group comprise antibodies targeting the offending
agent, gliadin. Key laboratory investigations
comprise the determination of autoantibodies against
TTG or endomysium (EmA), antibodies against
deamidated gliadin peptides and the CD-associated
human leukocyte antigens (HLA) DQ2 and DQ8.
Newly published guidelines confirm the pivotal role
of serological testing in CD diagnostics.
The European Society of Paediatric
Gastroenterology, Hepatology and Nutrition
(ESPGHAN) and American College of
Gastroenterology guidelines on ‘Diagnosis and
Management of Celiac Disease’ recommend the
following:
l
In patients with CD, Immunoglobulin-A 		
(IgA) TTG antibody is the preferred single test in
individuals over the age of two years.
l

l

6

In high-probability patients both IgA and IgGbased testing, such as IgG-deamidated gliadin
peptides (DGPs) and IgA-TTG should be done
and intestinal biopsy should be pursued even if
serologic tests are negative.
If the anti-TTG antibody titer is very high
(>10 times upper normal limit), and if this

result is reinforced by other positive serology
and compatible HLA, it is not necessary to
perform a biopsy.
l

l

l

l

In subjects suspected of low IgA or selective IgA
deficiency, total IgA and IgG-based testing (IgGDGPs and IgG-TTG) should be performed.
In patients on a gluten-containing diet all 		
diagnostic serologic testing should be done.
Combining several tests for CD rather than
IgA-TTG alone may increase the sensitivity for
CD, especially in high risk group.
Screening children younger than 2 years of age,
the IgA TTG test should be combined with DGP
(IgA and IgG).

Diagnostic tests should be carried out in individuals
on a gluten-containing diet. A gluten challenge is
only performed under exceptional circumstances.
Antibodies against Tissue Transglutaminase
Autoantibodies against TTG are the most important
serological markers for CD. They are alternatively
known as EmA, depending on the testing
method used: EmA are determined using indirect
immunofluorescence, while anti-TTG is detected
using immunoassay test systems such as ELISA.
EmA and anti-TTG antibodies of immunoglobulin
class IgA possess a very high sensitivity and
specificity for CD. They virtually never occur in
healthy individuals or patients with other intestinal
diseases, whereas in untreated CD their prevalence is
near 100 percent. Enzyme immunoassays for detection
of anti-TTG antibodies are preferred due to their
simplicity, cost-effectiveness, and automatability,
combined with their high sensitivity and specificity.
A multitude of clinical studies have confirmed the
efficacy of ELISA method, yielding a sensitivity of 90
percent to 100 percent and a specificity of 95 percent
to 100 percent for active CD.
Antibodies against deamidated gliadin peptides
Antibodies against gliadin also occur in patients
with CD, and their determination strengthens a
diagnosis. Recent scientific knowledge has revealed
that only a tenth of the epitopes of the gliadin
molecule are diagnostically relevant, and these must
be present in deamidated form. These immunoassays
assays provide significantly higher sensitivity and
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specificity than conventional anti-gliadin assays.
Multiple studies have shown that the new test yielded
sensitivity (at 95 percent specificity) of 83 percent/94
percent (IgA/IgG).
Anti-DGP antibodies are a relatively new biomarker
for CD diagnosis and management, recently this
marker is introduced at clinical laboratories of Aga
Khan University. Use of the anti-DGP antibodies
in combination with the anti-TTG are shown to
significantly increase the serological detection rate
for CD. This biomarker is particularly valuable for
identifying CD patients with an IgA deficiency,
which is frequently associated with CD and in
situations where biopsy cannot be performed due
to any reason. Determination of antibodies against
deamidated gliadin is also suitable for assessing
disease activity and for monitoring a gluten-free diet
or a gluten-load test.
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In conclusion the confirmation of a diagnosis of CD
should be based on a combination of findings from
the medical history, physical examination, serology,
and upper endoscopy with histological analysis of
multiple biopsies of the duodenum. While patients
with CD should be monitored regularly for residual
or new symptoms, adherences to gluten free diet
and assessment for complications. Monitoring of
adherence to gluten free diet should be based on a
combination of serology (IgA-TTG or IgA/IgG-DGP
antibodies). In children, special attention to assure
normal growth and development is recommended.
References:
A. R. Tapia et al. ‘ACG Clinical Guidelines: Diagnosis and
Management of Celiac Disease’. The American Journal of
Gastroenterology. Vol 108; May 2013.
S. Husby et al. ‘European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition Guidelines for the Diagnosis of
Coeliac Disease’. JPGN. Volume 54; Jan 2012.

Pathophysiology of Paroxysmal Nocturnal
Haemoglobinuria and Diagnosis by
Flowcytommetry
Dr Nadia Nasir
Hematology

Paroxysmal Nocturnal Hemoglobinuria (PNH)
is a rare, acquired stem cell disorder caused by
a somatic mutation in the X-linked PIG-A gene.
The PIG-A protein is involved in the initial stage
of synthesis of the glycosylphosphatidyl-inositol

(GPI) anchors. There is a partial or absolute
defect in the biosynthesis and expression of
glycophosphatidylinositol V (GPI) linked structures
including CD55 and CD59 on red cells. Absence
of these anchors on red cells is largely responsible
for intravascular hemolysis associated with clinical
PNH.
PNH has three distinctive clinical features that
vary greatly from patient to patient and during the
course of the disease. First, there is complement
mediated and predominantly intravascular hemolysis.
These result in clinical features such as, erectile
dysfunction, chronic renal failure, pulmonary
hypertension, anemia, and,hemoglobinuria.

Figure 1: Pathogenesis of PNH adapted from Haematologica April 2010
95: 523-526

Second, there is a characteristic thrombotic tendency
that occurs in extremities along with hepatic portal
(Budd-Chiari Syndrome), splenic, or mesenteric
veins.
Third, there is underlying bone marrow failure,
which occurs to some degree in all patients, and in
7
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its most extreme form, presents as immune-mediated
severe aplastic anemia.
Diagnosis by Flow Cytommerty
1. RBC Antigen Assays
These were the first used to detect PNH because
DAF (CD55) and MIRL (CD59) were recognized
early on as the proteins whose deficiency was central
to the pathophysiology of PNH. However testing
of RBCs alone in a routine assay is not adequate
for evaluation of these patients, because during
acute hemolytic episodes, inadequate red blood
cells are available for testing, hence such assays can
undersestimate the size of a PNH clone.
2. Leukocyte Analysis

Image adapted from Guidelines for the Diagnosis and Monitoring PNH and Related disorders by flowcytometry; Cytometry
Part B (Clinical Cytometry) 78B:211–230 (2010)

Assessment of PNH populations in leukocytes is
widely recognized as the best method for assessing
the true size of a PNH clone especially monocytes
and granulocytes. Lymphocytes are not a suitable
target because of their long life span and variable
expression of many GPI-linked proteins. Both
monocytes and neutrophils are analysed together to
increase sensitivity of the test. Monocytic markers
include CD14 and CD33 whearas granulocytic
markers include CD66.

GPI anchor and is absent from GPI anchor–deficient
granulocytes and monocytes.

3. Analysis by FLAER

C: Display of FLAER and CD24 on the CD15
population showing a clear double negative PNH
granulocyte population.

One of best reagents available to study GPI-linked
antigens on leukocytes is the reagent fluorescent
aerolysin or FLAER. This is a fluorochromeconjugated inactive variant of the bacterially derived
protein aerolysin, which binds specifically to the

A: Initial gate set on a CD45/SSC shows both
granulocytes and monocytes
B: Display of CD33 vs. CD15. Granulocytes
(CD15 high, CD33) low are clearly separated from
monocytes (CD15 low CD33 high) and are easily
distinguished.

D: Display of FLAER and CD14 on the CD33
positive population showing a clear double negative
PNH monocyte population.

Pathological Changes in Renal Transplant
Biopsies not Related to Allo-Immune
Mechanisms
Dr Mohammad Usman and Dr Saroona Haroon
Histopathology

In renal transplant recipients, a variety of factors
lead to renal damage apart from the allo-immune
reactions. These morphologic features observed in
these conditions can be either directly related to
8

immunosuppressive drugs or the sequelae of the
immunosuppressive state. Protocol for obtaining
and evaluation of renal biopsy in these conditions is
similar to that of a non-transplant biopsy.
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Calcineurin Inhibitor (CNI) Drug Toxicity
Calcineurin inhibitors (CNIs) including
cyclosporine (CsA) and tacrolimus are used for
maintenance immunosuppression after solid organ
transplantation. These drugs have the potential to
cause both acute and chronic nephrotoxicity. Acute
CNI toxicity is one of the important causes of acute
graft dysfunction. Acute tubular injury (ATI) is the
most common lesion, accompanied by isometric
vacuolization of tubular epithelial cell cytoplasm.
Both drugs also cause thrombotic microangiopathy
(TMA) and microvascular toxicity which manifests
as endothelial cell swelling, mucinous intimal
thickening, nodular hyalinosis, and focal medial
necrosis. Chronic CNI toxicity results in nodular
arteriolar hyalinosis (Figure-1), characterized by

Figure 2: Polyoma (BK) virus infection. Epithelial cells exhibiting
intranuclear viral inclusions.

necessary for its successful management. PTLD is
characterized by a monomorphic or polymorphic
lymphocytic infiltrate containing plasma cells,
many of which are atypical. There is typically a
diffuse interstitial infiltrate without associated
tubulitis or arteritis. Immunophenotyping of
lymphocytes helps in the definite diagnosis of its
concurrence with rejection.
Acute Tubular Necrosis (ATN)

Figure 1: CNI toxicity manifesting as vasculopathic changes including
nodular hyalinosis of arteriolar wall and intimal thickening.

hyaline, eosinophilic deposit consisting of fibrin,
IgM, C3, and C1q. The ischemic injury caused by
vasculopathy leads to interstitial fibrosis.
Infections
Urinary tract infections are common in the
early post-transplant period as the recipients are
predisposed to bacterial, fungal, protozoal, and viral
infections due to immunosuppression.
The infective agents may affect the allograft or the
native organs of the recipient. Bacterial infections
result in a mixed inflammatory cell infiltrate in the
interstitium associated with tubular microabscesses.
Cytomegalovirus (CMV) and polyoma (BK) viruses
are important causative agents (Figure 2).
Post-Transplant Lymphoproliferative Disorder
(PTLD)
It is a rare disorder which is an important
differential diagnosis with acute cellular rejection
and an early diagnosis of this complication is

Acute tubular injury (ATI) or ATN is the main
cause of primary nonfunction of the allograft. ATI
results from a multitude of causes and including
in situ injury in the donor; ischemia during organ
harvesting, storage, or transportation of the organ;
and ischemic injury incurred perioperatively in the
recipient. The morphological picture is similar to
that seen in the native kidneys. The histological
features of ATN do not correlate well with the
allograft function.
Acute Tubulointerstitial Nephritis (ATIN)
Non-immune related ATIN may result from
a number of insults such as infection, drug
hypersensitivity, viral infection, etc. A
predominance of neutrophils in the mixed
inflammatory cell infiltrate in the interstitium,
especially if associated with tubular microabscesses
or leucocyte casts favor the possibility of infection.
A predominance of eosinophils raises the possibility
of drug hypersensitivity. Viral infections are
accompanied by appropriate viral cytopathic effects
in addition to the infiltrate.
Recurrent and De Novo Renal Diseases
Almost all diseases that occur in the native kidneys
can occur de novo or recur in transplant kidneys.
9
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Glomerular diseases account for approximately
10-20 percent of cases of ESRD undergoing
transplantation, and overall approximately 20
percent of these patients experience recurrence.
The same disease can also occur as de novo
disease in the transplanted kidneys. Disease
characteristics of the recurrent disease are similar
to those of the original disease, but are usually
mild in nature. The two most common diseases
are membranous glomerulonephritis and focal
segmental glomerulosclerosis. A non-glomerular
disease that frequently recurs in transplanted

kidneys is the primary hyperoxaluria, if kidney
transplantation is carried out without concomitant
liver transplantation.
Conclusion
Knowledge of the pathologic features either
related to allo-immune rejection or other
conditions in post-transplant patients is
necessary to identify, prevent and minimize
the damage by administering proper treatment
and management.

Myelodysplastic Syndromes
Dr Aeysha Majeed
Hematology

The Myelodysplastic syndromes (MDS) are a
group of clonal disorders of the bone marrow. Their
common feature is bone marrow failure as a result
of ineffective haematopoiesis rather than reduced
haematopoietic activity. MDS is predominantly a
disease of the elderly, although it may affect all ages.
It can arise de novo or follow previous chemotherapy
or radiotherapy for another malignancy.

Classification
French-American-British (FAB) classification
In 1974 and 1975, a group of pathologists from
France, the US, and Britain produced the first widely
used classification of these diseases. This - FrenchAmerican British classification was published in
1976, and revised in 1982.

Table 1: (adapted from text book Postgraduate Haematology by Hoffbrand 6th edition)
Name

Description

Refractory anemia (RA

Characterized by less than 5% primitive blood cells (myeloblasts) in the bone marrow and
pathological abnormalities primarily seen in red cell precursors

Refractory anemia with ring
sideroblasts (RARS

Also characterized by less than 5% myeloblasts in the bone marrow, but distinguished by the
presence of 15% or greater red cell precursors in the marrow being abnormal iron-stuffed cells
”called “ringed sideroblasts

Refractory anemia with excess Characterized by 5-20% myeloblasts in the marrow
blasts (RAEB)
Refractory anemia with excess Characterized by 21-30% myeloblasts in the marrow (>30% blasts is defined as acute myeloid
blasts in transformation
)leukemia
)(RAEB-T
Chronic myelomonocytic
leukemia (CMML), not to
be confused with chronic
myelogenous leukemia or CML

Characterized by less than 20% myeloblasts in the bone marrow and greater than 1*109/L
.monocytes (a type of white blood cell) circulating in the peripheral blood

World Health Organization
Most recently, the WHO has evolved a new
classification scheme (2008) which is based more
on genetic findings. However, morphology of

10

the cells in the peripheral blood, bone marrow
aspirate, and bone marrow biopsy is still the
screening test used in order to decide which
classification is best and which cytogenetic
aberrations may be related.
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Table 2: (adapted & modified from text book Postgraduate Haematology by Hoffbrand 6th edition).
Old System

New System

Refractory anemia (RA)

Refractory cytopenia with unillineage dysplasia (Refractory anemia, Refractory neutropenia
and Refractory thrombocytopenia)

Refractory anemia with ringed sideroblasts (RARS)

Refractory anemia with ring sideroblasts (RARS)
Refractory anemia with ring sideroblasts – thrombocytosis (RARS-t) (provisional entity)
which is in essence a myelodysplastic/myeloproliferative disorder and usually has a JAK2
mutation (janus kinase) – New WHO classicication 2008
Refractory cytopenia with multilineage dysplasia’ (RCMD)’ includes the subset Refractory
cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). RCMD includes patients with pathological changes not restricted to red cells (i.e., prominent white cell precursor
and platelet precursor (megakaryocyte) dysplasia.

Refractory anemia with excess blasts
(RAEB)

Refractory anemias with excess blasts I and II. RAEB was divided into RAEB-I (5-9%
blasts) and RAEB-II (10-19%) blasts, which has a poorer prognosis than RAEB-I. Auer rods
may be seen in RAEB-II which may be difficult to distinguish from acute myeloid leukemia.

Refractory anemia with excess blasts
in transformation (RAEB-T)

This category was eliminated, such patients are now considered to have acute leukemia

Chronic myelomonocytic leukemia
(CMML)

CMML was removed from the myelodysplastic syndromes and put in a new category of
myelodysplastic-myeloproliferative overlap syndromes.

5q - syndrome, typically seen in older women with normal or high platelet counts and
isolated deletions of the long arm of chromosome 5 in bone marrow cells, was added to the
classification.

Myelodysplasia unclassifiable (seen in those cases or megakaryocyte dysplasia with fibrosis
and others)
Refractory cytopenia of childhood (dysplasia in childhood) – New in WHO classification
2008

Diagnosis
Morphology
The diagnosis of MDS depends on careful
morphological examination of the blood film and
bone marrow aspirate and trephine specimens.
Common abnormalitiesinclude:
l

l

Peripheral blood. Red cells – anisopoikilocytosis,
macrocytosis. Neutrophils – hypogranulation
(decrease granules), pseudo- Pelger forms(bi-lobed
neutrophils). Platelets – giant forms (large sized).
Bone marrow. Erythroid cells – multinuclearity,
nuclear budding, ring sideroblasts.
Myeloid cells show hypogranularity, increased
blast cells. Megakaryocytes – giant forms or
micromegakaryocytes.

Where there are changes in all three lines the
term ‘trilineage dysplasia’ is used. The bone
marrow trephine biopsy usually confirms marrow

hypercellularity, although fibrosis and even
hypocellularity may occur.
Genetics
Around 50 percent of cases of MDS show
cytogenetic abnormalities. Common changes include
monosomy 7 or 7q−, trisomy 8and monosomy 5 or
5q−. The incidence of chromosome abnormalities
increases with the severity of the disease and risk of
leukaemic transformation.
Management
The goals of therapy are to control symptoms, improve
quality of life, improve overall survival, and decrease
progression to acute myelogenous leukemia (AML). The
International Prognostic Scoring System (IPSS) – based
on the number of blood cytopenias, percentage of bone
marrow blasts and karyotype – is simple prognostic tool
which can be used to direct treatment.Supportive care
with blood product support and hematopoeitic growth
factors (e.g. erythropoietin) is the mainstay of therapy.
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Fluorescent Optical Method for Platelet
Estimation: An Advanced Clinical Parameter
in Laboratory Hematology
Noor Rahman Khan and Muhammad Shariq Shaikh
Hematology

Platelets, also called “thrombocytes”, are a
component of blood whose function (along with
the coagulation factors) is to stop bleeding by
clumping and clogging blood vessel injuries.
Platelets are cytoplasmic fragments of
megakaryocytes of the bone marrow and hence
lack nucleus. Approximately 70 to 80 percent of
platelets circulate in the blood, 20 to 30 percent
are stored in the spleen. A normal platelet count
ranges from 150,000 to 450,000 platelets per
microliter of blood.

their size. In a normal specimen, erythrocytes
which also are non-nucleated cells can be
clearly distinguished from platelets based on
difference in their size. However in pathological
conditions, where platelets are larger than 30 fL
(e.g. large and giant platelets in Bernard-Soulier
Syndrome) or when erythrocytes are smaller than
25 fL (e.g. red cell fragmentation syndromes
or microcytosis) a clear separation may not be
achieved. In such cases, platelet count must be
verified by an alternate method.

Complete blood count (CBC) is a basic test
ordered routinely by physicians as a part of initial
diagnostic work-up on their patients. Platelet
count estimation is an important integral part of
a CBC report and its reliability is highly desired
in the diagnostic and treatment process of several
clinical conditions. For instance, it is very
important to know the accurate platelet count
of a patient with thrombocytopenia to decide
appropriate treatment strategy particularly when
platelet transfusion is also being considered.

Fluorescent optical method of platelet estimation
is an advanced technique in which the platelet
RNA is first stained with a patented fluorescence
dye specifically developed for diode lasers.
Subsequently, the platelets are recorded flowcytometrically by means of semi-conductor
laser technology. As erythrocytes and platelets
differ in their RNA content, this nucleic acid
staining enables the analyzer system to properly
differentiate platelets from other cells.

Various methods for platelet estimation can be
utilized like microscopy using a haemocytometer,
immunophenotyping utilizing monoclonal
antibodies and a flow cytometer, impedance
method and the fluorescent optical method.
The majority of modern automated hematology
analyzers in use incorporate the impedance
method for platelet estimation.
In impedance measurement (resistance measuring
principle), cells are passed one after the other
through a capillary opening. The passing cell
produces an electrical resistance and thus an
electronic signal which is proportionate to its
volume. Hence, the cells are identified based on
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Several models of Sysmex X-class hematology
analyzers incorporate this sophisticated
optical method of platelet estimation. At
AKUH clinical laboratories, the state-of-theart Sysmex XE-5000 automated hematology
analyzer (Sysmex Corporation, KOBE, JAPAN)
can perform platelet counts by both impedance
and optical methods. In case of interference in
the platelet impedance count, the instrument
automatically alerts the user to switch to
optical method. An automatic algorithm using
pre-defined criteria can also be activated for
this purpose. Thus fulfilling the requirements
of good laboratory practice, an accurate and
precise platelet count result is reported on
every patient specimen.
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Introduction of Beta-D-Glucan and
Galactomannan Testing for Diagnosis of
Invasive Fungal Infections
Dr Tazeen Fatima
Clinical Microbiology

Fungi are increasingly reported as major pathogens
in critically ill and immunocompromised patients.
Invasive fungal diseases are important causes of
morbidity and mortality today. Several factors are
considered to contribute in the increasing trend of
invasive fungal infections, including hematological
malignancies, stem cell transplantation, use of
chemotherapeutic drugs and immunosuppressive
agents, broad-spectrum antibiotics, prosthetic
devices and grafts, and more aggressive surgery.
Patients with burns, neutropenia and HIV infection
are also predisposed to fungal infections. Yeasts
most frequently seen in clinical practice are Candida
spp and Cryptococcus spp. The most frequent
filamentous fungi (molds) isolated are Aspergillus
spp., but Fusarium spp., Scedosporium spp. and
Mucoraceous molds are increasingly seen.

Current guidelines regarding diagnosis of IFI
recommends use of fungal cell wall antigens like
Beta-D Glucan and galactomannan in serum or
Bronchoalveolar lavage (BAL) fluid. Beta-D glucan
is a found in most fungi, both yeasts and molds,
while galactomannan is specific to Aspergillus. High
levels can be detected in serum or BAL fluid, which
can help diagnose IFI early and can also guide in
commencement of therapy as it has both diagnostic
as well as prognostic impact. Use of these antigens in
diagnosis and monitoring of IFIs has led to decrease
in unnecessary use of antifungals.

The symptoms of invasive fungal infections (IFI)
are nonspecific which can impede timely diagnosis.
Definitive diagnosis of invasive fungal infections
requires cultures of tissue, blood, or other fluids.
Routine diagnostic tests are time consuming, so
empirical treatment can be commenced, based on
clinical suspicion, which can also make a specific
fungal diagnosis difficult. Fungal infections of the
airway may be evident on chest radiography or
computed tomography. Bronchoscopy is also used to
better visualize the infected area and to obtain tissue
samples.

Galactomannan levels, however, can be falsely
normal, especially if the patient is already on
antifungal treatment. Falsely normal levels
are also witnessed in chronic granulomatous
diseases and Job’s syndrome. Falsely positive
results are seen in patients with altered intestinal
barrier (galactomannan is also found in certain
foods e.g. cereals), in patients on treatment with
piperacillin-tazobactam or amoxicillin-clavulanate
and in patients infected with Penicillium,
Histoplasma, Alternaria, Paecilomyces or
Geotrichum. Beta-D Glucan levels usually do
not rise in infections due to mucoraceous molds
(Rhizopus, Mucor) and Cryptococcus neoformans.
Falsely high results are seen when patient is
on beta lactam antibiotics or hemodialysis or if
specimen is contaminated with talc.

Aspergillosis is common in patients with
hematological malignancies. Invasive
aspergillosis manifests primarily as pneumonia
or sinus infections, or asymptomatic lesions in
the lung parenchyma. It is rapidly progressive
and can disseminate hematogenously. Definitive
diagnosis of Invasive Aspergillosis (IA) can be
made on histopathology and culture on biopsy
tissue from suspected site. Obtaining such
specimens can be a hurdle as it requires invasive
procedure, which is not always possible and can
delay diagnosis in this regard.

Regarding galactomannan, a single positive index
of >0.7 or two consecutive samples of >0.5 in
serum is considered to be positive and < 0.5 is
negative. Serum value of >1.0 is considered a sign
of therapeutic failure. In BAL sample, a single
positive index of >1.0 is positive. In CSF sample a
single positive index of >0.5 is positive. For Beta-D
Glucan, data for neonates and infants less than
six months are lacking. It is considered positive if
levels are >80 pg/ml, Indeterminate if 60-80 pg/ml
(repeat test recommended) and negative if levels
are <60 pg/ml.
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These tests have been introduced in Clinical
Microbiology Laboratory at Aga Khan University
Hospital. These investigations can be done in
patients with high clinical suspicion of IFI like

aspergillosis, candidemia, etc. The results must
always be correlated to the clinical history,
radiological findings and culture results before
making the final diagnosis.

Basic Concepts in Hematopoietic Stem Cell
Transplantation
Dr Muhammad Hasan
Haematology

Hematopoietic stem cell transplantation (HSCT)
is the therapeutic modality of transplanting blood
containing hematopoietic stem cells for treating
refractory blood diseases like leukemia and aplastic
anemia, some solid tumors and also refractory
autoimmune diseases.
Hematopoietic stem cells are cells that in due
course become RBCs, WBCs and platelets. These
have regenerative capacity and are located in bone
marrow but can be mobilized to peripheral blood
due to G-CSF, severe infections and treatment with
antineoplastic drugs. Cord blood also contains
these cells. Accordingly HSCT can be classified
as per type of blood that contains these stem cells
into: Bone marrow transplant (BMT), Peripheral

blood stem cell transplant (PBSCT) and Cord blood
transplant (CBT).
It can also be classified a/c to source of stem cells
into:
1. Autologous: When transplanted blood is of
		patient him/herself.
2. Allogeneic: When the blood is obtained
		 from another person.
		 a. Syngeneic: if donor is identical twin.
		 b. Allogeneic related: If donor is blood
			 relative other than an identical twin
		 c. Allogeneic unrelated: When donor is an
			unrelated person.

Common Indications:
Allogeneic

Autologous
Multiple myeloma

AML, ALL , MDS

Non-Hodgkin lymphoma

CML and other MPDs

Hodgkin disease

Chronic lymphocytic leukemia

Acute myeloid leukemia

Multiple myeloma

Neuroblastoma

Non-Hodgkin lymphoma and Hodgkin disease

Germ cell tumors

Thalassemia major and Sickle cell anemia

Autoimmune disorders - SLE, systemic sclerosis

Inherited bone marrow failure syndromes

Amyloidosis

Aplastic anemia, PNH and pure red cell aplasia
Severe combined immunodeficiency (SCID)
Inborn errors of metabolism - Eg,
mucopolysaccharidosis and Gaucher disease
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HSCT Procedure
Selection of donor (for allogeneic HSCT
Stem cells are normally obtained from an HLA
matched donor (Usually sibling). When no donor is
available among blood relatives, a search is made
for an unrelated matched donor. Allogeneic HSCT
is also possible even if there is not a perfect HLA
match between donor and patient (mismatch HSCT),
but the chance of severe GVHD and graft failure is
high. Once the donor is identified, he is screened for
general health and well being.
Pretransplant Conditioning
The patient is given chemotherapy and
radiotherapy to kill all cancer cells and to
eliminate or weaken normal blood cells, to
create favorable environment for transplanted
stem cells to get grafted. This makes the patient
immunocompromised so there is need of isolation
in bio clean room and provision of antifungal,
antiviral and antibacterial drugs. Conditioning
starts approx 7-10 days before transplantation of
stem cells.
Harvesting Hematopoietic Stem Cells
From bone marrow: It is done under general
anesthesia, through a bone marrow aspirate needle by
repeatedly inserting it into the iliac bone to acquire
the bone marrow in amount 15ml/kg of patient’s
body weight. A dose of 1 X 108 and 2 X 108marrow
mononuclear cells per kilogram are required to
establish engraftment in autologous and allogeneic
marrow transplants, respectively.
From peripheral blood: Stem cells are collected once
they peak in peripheral blood after the administration
of G-CSF. This is done using blood cell separator
(Aphresis) which efficiently separates a fraction
of stem cells through centrifugal separation. For

a typical donor, approximately 24 L of whole
blood can be processed over two days to collect
approximately 500 million CD34+ cells, a cell
progenitor population enriched for hematopoietic
stem cells.
In Autologous HSCT, harvesting is done before
conditioning. In allogeneic HSCT, donor has to be
hospitalized for few days for pre-harvest health
check, harvesting and health check after collection.
Transplantation of Stem Cells
The collected stem cells are then transfused to patient
through intravenous route. This is just like routine
blood transfusion.
Engraftment and Hematopoietic Recovery
Engraftment is the hematopoietic reconstitution i.e.
the start of blood cell formation by infused stem
cells in the recipient’s bone marrow. Normally the
day on which absolute neutrophil count reaches at
least 500/uL for three consecutive days for the first
time is taken as the date of engraftment. It usually
takes several weeks before the number of blood cells
starts to return to normal. In some people, it may take
longer.
Transfusion of blood products is required
throughout the process from conditioning to time of
hematopoietic recovery.
After the Transplant
Usually the patient is discharged from the hospital
approximately one - two months after transplantation.
He/she remains on immunosuppressive and anti
microbial drugs for a certain period to avoid GVHD
and infections. The speed of recovery and return to
productive life varies, depending on patient’s age,
condition, disease involved and post-transplant
complications.
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